
## Mohammad I Saleh

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5450125/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Population Pharmacokinetics of Ibrutinib in Healthy Adults. European Journal of Drug Metabolism and Pharmacokinetics, 2021, 46, 405-413.	0.6	0
2	Population Pharmacokinetics Modeling of Lamotrigine in Jordanian Epileptic Patients Using Dried Blood Spot Sampling. Drug Research, 2021, 71, 429-437.	0.7	2
3	A systematic review of population pharmacokinetic analyses of digoxin in the paediatric population. British Journal of Clinical Pharmacology, 2020, 86, 1267-1280.	1.1	20
4	Bayesian Population Pharmacokinetic Modeling of Eltrombopag in Chronic Hepatitis C Patients. European Journal of Drug Metabolism and Pharmacokinetics, 2019, 44, 31-42.	0.6	1
5	A time-to-event analysis describing virologic response in patients with chronic hepatitis C infection. Journal of Chemotherapy, 2019, 31, 274-283.	0.7	1
6	Clarithromycin laurate salt: physicochemical properties and pharmacokinetics after oral administration in humans. Pharmaceutical Development and Technology, 2019, 24, 607-615.	1.1	2
7	Patient characteristics associated with peglyated interferon alfaâ€2a induced neutropenia in chronic hepatitis C patients. Clinical and Experimental Pharmacology and Physiology, 2018, 45, 636-642.	0.9	4
8	Evaluation of the impact of waterpipe tobacco smoke exposure on the activity and expression of rat hepatic CYP450: a pharmacokinetic study. Inhalation Toxicology, 2018, 30, 519-526.	0.8	3
9	Population pharmacokinetics of vancomycin in Jordanian patients. Tropical Journal of Pharmaceutical Research, 2018, 17, 351.	0.2	1
10	Predictors of nonadherence in children and adolescents with epilepsy: A multimethod assessment approach. Epilepsy and Behavior, 2018, 85, 205-211.	0.9	12
11	A population pharmacodynamic model characterizing neutropenia associated with pegylated interferon alpha 2-a therapy in patients with chronic hepatitis C viral infection. Naunyn-Schmiedeberg's Archives of Pharmacology, 2018, 391, 953-963.	1.4	2
12	Predictors of Severe Thrombocytopenia Secondary to Peginterferon Alfa-2a Treatment in Subjects With Hepatitis C Virus Infection. American Journal of Therapeutics, 2017, 24, e670-e675.	0.5	4
13	A Bayesian Approach for Population Pharmacokinetic Modeling of Pegylated Interferon α-2a in Hepatitis C Patients. Clinical Pharmacokinetics, 2017, 56, 1369-1379.	1.6	5
14	Clinical Predictors Associated With Warfarin Sensitivity. American Journal of Therapeutics, 2016, 23, e1690-e1694.	0.5	9
15	Pharmacogenetic-guided Warfarin Dosing Algorithm in African-Americans. Journal of Cardiovascular Pharmacology, 2016, 67, 86-92.	0.8	28
16	Eltrombopag dose predictors in thrombocytopenic subjects with hepatitis C virus infection. Clinical and Experimental Pharmacology and Physiology, 2015, 42, 1030-1035.	0.9	6
17	Modeling Longitudinal Changes in Buprenorphine Treatment Outcome for Opioid Dependence. Pharmacopsychiatry, 2014, 47, 251-258.	1.7	4
18	Dosage Individualization of Warfarin Using Artificial Neural Networks. Molecular Diagnosis and Therapy, 2014, 18, 371-379.	1.6	25

#	Article	IF	CITATIONS
19	Predictors of long term opioid withdrawal outcome after short-term stabilization with buprenorphine. European Review for Medical and Pharmacological Sciences, 2014, 18, 3935-42.	0.5	4
20	Population pharmacodynamic analysis of erythropoiesis in preterm infants for determining the anemia treatment potential of erythropoietin. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2013, 304, R772-R781.	0.9	15
21	Comparison of red blood cell survival in sheep determined using red blood cells labeled with either biotin at multiple densities or [ <sup><b>14</b></sup> C]cyanate: validation of a model to study human physiology and disease. Transfusion, 2012, 52, 963-973.	0.8	5
22	Pharmacodynamic analysis of stress erythropoiesis: change in erythropoietin receptor pool size following double phlebotomies in sheep. Biopharmaceutics and Drug Disposition, 2011, 32, 131-139.	1.1	5
23	Correction for effect of cold storage on immature platelet fraction. Journal of Clinical Laboratory Analysis, 2010, 24, 431-433.	0.9	10
24	Evidence of Receptor-Mediated Elimination of Erythropoietin by Analysis of Erythropoietin Receptor mRNA Expression in Bone Marrow and Erythropoietin Clearance During Anemia. Journal of Pharmacology and Experimental Therapeutics, 2010, 333, 528-532.	1.3	23